Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is poised for growth and diversification in various markets and their continuous innovation and strong partnerships with healthcare providers give them a competitive edge. Additionally, their strong financial performance, with a current P/E ratio of 48.26, indicates a positive outlook for investors. However, potential risks such as regulatory delays and competition in the medical device industry should be carefully monitored. Overall, Edwards Lifesciences' impressive track record and promising future make it a solid investment choice for long-term growth.

Bears say

Edwards Lifesciences is a leader in advanced structural heart disease technologies, with an established portfolio of successful products. However, potential risks include competition from new market entrants and innovation from existing competitors, as well as potential delays in regulatory approvals or clinical trials. Furthermore, changing market dynamics and negative clinical data could affect the company's growth potential and profitability.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.